Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23754007 | 0.90 | TRPV4 (0.35) | TRPV4EGFRPTP4A3 | |
| SCHEMBL31173036 | 0.83 | AR (0.39) | — | |
| SCHEMBL31172914 | 0.83 | ALDH1A1 (0.50) | — | |
| SCHEMBL3033594 | 0.79 | EGFR (0.34) | EGFR | |
| SCHEMBL25992033 | 0.77 | TRPV4 (0.34) | TRPV4 | |
| SCHEMBL48778 | 0.77 | PTP4A3 (0.49) | TRPV4EGFRPTP4A3 | |
| SCHEMBL17345393 | 0.77 | AR (0.36) | — | |
| SCHEMBL2800490 | 0.73 | TRPV4 (0.52) | TRPV4EGFR | |
| SCHEMBL6899726 | 0.73 | ALDH1A1 (0.47) | EGFR | |
| SCHEMBL7951535 | 0.72 | XDH (0.46) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2025-11-25 | — | — | US | disclosed |
| CN-116120287-B | Heteroaromatic carboxamide derivatives as inhibitors of plasma kallikrein | 勃林格殷格翰国际有限公司 | 2025-01-28 | — | — | CN | disclosed |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-03-07 | — | — | US | disclosed |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2024-01-04 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| CN-116120287-A | Heteroaromatic carboxamide derivatives as inhibitors of plasma kallikrein | 勃林格殷格翰国际有限公司 | 2023-05-16 | — | — | CN | disclosed |
| EP-4103562-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| CN-115052873-A | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | 勃林格殷格翰国际有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-09-23 | — | — | US | disclosed |
| WO-2021160718-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021160718-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479827-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | TRPV4 3413/4885EGFR 1445/4885PTP4A3 4625/4885 |
| US-20210292301-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | TRPV4 3413/4885EGFR 1445/4885PTP4A3 4625/4885 |
| US-11760745-B2 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | TRPV4 3413/4885EGFR 1445/4885PTP4A3 4625/4885 |
| US-20240002363-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | TRPV4 3413/4885EGFR 1445/4885PTP4A3 4625/4885 |
| US-20240076286-A1 | HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | TRPV4 3413/4885EGFR 1445/4885PTP4A3 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.